All Metrics
GEHC Valuation Metrics
GEHC Stock Price Metrics
GEHC Dividend Metrics
GEHC Growth Rate Metrics
GEHC Discounted Cash Flow Metrics
| Fair Value Price | $166.30 |
| Margin of Safety | 152.88% |
GEHC Revenue Metrics
GEHC PE Ratio Metrics
| PE Ratio | 20.11 |
| PE Ratio Avg TTM | 17.54 |
| PE Ratio Avg 3Y | 20.60 |
| Current VS TTM Avg | +14.65% |
| Current VS 3Y Avg | -2.38% |
| Current VS 5Y Avg | -0.67% |
GEHC PS Ratio Metrics
| PS Ratio | 1.51 |
| PS Ratio Avg TTM | 1.73 |
| PS Ratio Avg 3Y | 1.81 |
| Current VS TTM Avg | -12.77% |
| Current VS 3Y Avg | -16.67% |
| Current VS 5Y Avg | -16.81% |
GEHC PB Ratio Metrics
| PB Ratio | 2.82 |
| PB Ratio Avg TTM | 3.40 |
| PB Ratio Avg 3Y | 4.24 |
| Current VS TTM Avg | -17.14% |
| Current VS 3Y Avg | -33.53% |
| Current VS 5Y Avg | -33.53% |
GEHC Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 19.77 |
| PFCF Ratio Avg TTM | 23.07 |
| PFCF Ratio Avg 3Y | 22.37 |
| Current VS TTM Avg | -14.29% |
| Current VS 3Y Avg | -11.60% |
| Current VS 5Y Avg | -10.63% |
GEHC Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.99 |
| Debt/Equity Ratio Avg TTM | 1.03 |
| Debt/Equity Ratio Avg 3Y | 1.22 |
| Current VS TTM Avg | -3.67% |
| Current VS 3Y Avg | -18.85% |
| Current VS 5Y Avg | +23.88% |
GEHC PEG Ratio Metrics
| PEG Ratio | 4.14 |
| PEG Ratio Avg TTM | 2.27 |
| PEG Ratio Avg 3Y | 2.27 |
| Current VS TTM Avg | +81.98% |
| Current VS 3Y Avg | +81.98% |
| Current VS 5Y Avg | +172.37% |
GEHC FCF Yield
| FCF Yield | 5.06% |
| FCF Yield Avg TTM | 4.40% |
| FCF Yield Avg 3Y | 4.53% |
| Current VS TTM Avg | +15.05% |
| Current VS 3Y Avg | +11.60% |
| Current VS 5Y Avg | +10.55% |
GEHC Earnings Yield
| Earnings Yield | 4.97% |
| Earnings Yield Avg TTM | 5.79% |
| Earnings Yield Avg 3Y | 5.05% |
| Current VS TTM Avg | -14.21% |
| Current VS 3Y Avg | -1.59% |
| Current VS 5Y Avg | -3.19% |
GEHC EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 15.42 |
| Ev/Ebit Ratio Avg TTM | 15.30 |
| Ev/Ebit Ratio Avg 3Y | 16.70 |
| Current VS TTM Avg | +0.77% |
| Current VS 3Y Avg | -7.65% |
| Current VS 5Y Avg | -7.82% |
GEHC EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 11.01 |
| Ev/Ebitda Ratio Avg TTM | 12.04 |
| Ev/Ebitda Ratio Avg 3Y | 13.36 |
| Current VS TTM Avg | -8.55% |
| Current VS 3Y Avg | -17.60% |
| Current VS 5Y Avg | -17.76% |
GEHC EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.03 |
| Ev/Assets Ratio Avg TTM | 1.13 |
| Ev/Assets Ratio Avg 3Y | 1.27 |
| Current VS TTM Avg | -9.20% |
| Current VS 3Y Avg | -18.86% |
| Current VS 5Y Avg | -18.86% |
GEHC EV/Sales Ratio Metrics
| Ev/Sales Ratio | 1.92 |
| Ev/Sales Ratio Avg TTM | 2.05 |
| Ev/Sales Ratio Avg 3Y | 2.18 |
| Current VS TTM Avg | -6.31% |
| Current VS 3Y Avg | -11.93% |
| Current VS 5Y Avg | -12.59% |
GEHC Current Ratio Metrics
| Current Ratio | 1.17 |
| Current Ratio Avg TTM | 1.12 |
| Current Ratio Avg 3Y | 1.10 |
| Current VS TTM Avg | +4.74% |
| Current VS 3Y Avg | +6.49% |
| Current VS 5Y Avg | +59.86% |
GEHC Quick Ratio Metrics
| Quick Ratio | 0.89 |
| Quick Ratio Avg TTM | 0.88 |
| Quick Ratio Avg 3Y | 0.85 |
| Current VS TTM Avg | +1.96% |
| Current VS 3Y Avg | +4.78% |
| Current VS 5Y Avg | +58.04% |
GEHC ROIC Metrics
| ROIC | 8.84% |
| ROIC Avg 3Y | 8.37% |
| ROIC Avg 5Y | 9.38% |
| Current VS 3Y Avg | +5.62% |
| Current VS 5Y Avg | -5.81% |
| Current VS 10Y Avg | +9.89% |
GEHC Return on Assets Metrics
| ROA | 5.65% |
| ROA Avg TTM | 5.83% |
| ROA Avg 3Y | 5.87% |
| Current VS TTM Avg | -3.17% |
| Current VS 3Y Avg | -3.67% |
| Current VS 5Y Avg | -61.97% |
GEHC Return on Equity Metrics
| ROE | 20.08% |
| ROE Avg TTM | 21.84% |
| ROE Avg 3Y | 21.53% |
| Current VS TTM Avg | -8.04% |
| Current VS 3Y Avg | -6.75% |
| Current VS 5Y Avg | -37.78% |
GEHC Net Profit Margin Metrics
| Net Profit Margin | 7.58% |
| Net Profit Margin Avg TTM | 8.34% |
| Net Profit Margin Avg 3Y | 8.77% |
| Current VS TTM Avg | -9.11% |
| Current VS 3Y Avg | -13.53% |
| Current VS 5Y Avg | -22.83% |
Last Updated: Monday, June 29, 2026
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini